Safety, Tolerability, and Effect of Alirocumab in High Cardiovascular Risk Patients With Severe Hypercholesterolemia Not Adequately Controlled With Conventional Lipid-modifying Therapies (ODYSSEY APPRISE)

Last updated:
2026-07-11
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

"A MULTI-COUNTRY, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO DOCUMENT THE SAFETY, TOLERABLITY AND EFFECT OF ALIROCUMAB ON ATHEROGENIC LIPOPROTEINS IN HIGH CARDIO-VASCULAR RISK PATIENTS WITH SEVERE HYPERCHOLESTEROLEMIA NOT ADEQUATELY CONTROLLED WITH CONVENTIONAL LIPID-MODIFYING THERAPIES."

Intervention/treatment:
ALIROCUMAB (SAR236553, REGN727)
Medical condition:
HYPERCHOLESTEROLEMIA
Protocol code:
LPS14245
Control number:
183721
Status:
Closed
Approved:
May 13, 2015
Date Completed:
Trial phase:
Phase 3
For more information:
ClinicalTrials.gov - NCT02476006
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
18 Years and older
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
Trial Transparency Team
Organization
Sanofi aventis recherche & développement
Phone:
800-633-1610
Extension 1#
Sponsor
SANOFI AVENTIS GROUP

Locations

Investigational Site Number 124001
Sherbrooke, J1H 5N4
Investigational Site Number 124002
Chicoutimi, G7H7K9
Investigational Site Number 124003
Québec, G1V4W2
Investigational Site Number 124005
Ottawa, K1Y4W7
Investigational Site Number 124007
Sarnia, N7T 4X3
Investigational Site Number 124008
London, N6A 4L6
Investigational Site Number 124009
Woodstock, N4S5P5
Investigational Site Number 124011
Vancouver, V5Y3W2
Investigational Site Number 124012
Victoria, V8T5G4
Investigational Site Number 124013
Hamilton, L8L 2X2
Investigational Site Number 124014
Toronto, M5B1W8
Investigational Site Number 124015
Cambridge, N1R6V6
Investigational Site Number 124017
Halifax, B3H1V7
Investigational Site Number 124018
Calgary, T2E7C5
Investigational Site Number 124019
Saint-Charles-Borromée, J6E6J2
Investigational Site Number 124020
Montreal, H2W1R7
Investigational Site Number 124022
Montreal, H4A3J1
Investigational Site Number 124023
Toronto, M4N3M5
Investigational Site Number 124024
Peterborough, K9J0B2
Investigational Site Number 124025
Edmonton, T6G2B7
Investigational Site Number 124026
Maple Ridge, V2X5Z6
Investigational Site Number 124027
Coquitlam, V3K3P4
Investigational Site Number 124028
Trois-Rivières, N7T 4X3
Investigational Site Number 124030
Smiths Falls, K7A4W8
Investigational Site Number 124031
Winnipeg, R2H2A6
Investigational Site Number 124032
Mount Pearl, A1N1W7

Results

See the results from the trial NCT02476006. This is an external link. The information is not authorized by the Government of Canada.

Date posted:
Did you find what you were looking for?